3SBio (HKSE:01530) Cash Received from Insurance Activities

View and export this data going back to 2015. Start your Free Trial

What is 3SBio Cash Received from Insurance Activities?

Cash Received from Insurance Activities only applicable to companies reporting Cash Flow from Operations in direct method.

3SBio (HKSE:01530) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3SBio Inc (HKSE:01530) » Definitions » Cash Received from Insurance Activities

Comparable Companies

Traded in Other Exchanges

83B:Germany

Address

No. 3 A1, Road 10, Shenyang Economy and Technology Development Zone, Shenyang, CHN, 110027

Website

https://www.3sbio.com

3SBio Inc, or 3SBio, is one of the largest and most established biotech drugmakers in China. In 2021, it reported revenue of CNY 6.3 billion. Approximately 90% of its revenue is derived from four core drugs: TPIAO (rhTPO), Yisaipu (biosimilar of etanercept, a TNF-alpha inhibitor), rhEPO, and Mandi (minoxidil). With the exception of minoxidil, an over-the-counter drug, the others are all older generation biologics. Most of the pipeline candidates are "me-too" drugs and in general are still at an early stage.

Executives

Blackrock, Inc.	2201 Interest of corporation controlled by you
Lou Jing	2305 Beneficiary of a trust
Jpmorgan Chase & Co.	2502 Approved lending agent
Hsbc Holdings Plc	2302 Custodian
Citic Securities Company Limited	2201 Interest of corporation controlled by you
Citron Pe Associates, L.p.	2201 Interest of corporation controlled by you
Citron Pe Funds Limited	2201 Interest of corporation controlled by you
Citron Pe Holdings Limited	2201 Interest of corporation controlled by you
Cpechina Fund, L.p.	2201 Interest of corporation controlled by you
Cs Sunshine Investment Limited	2101 Beneficial owner
Tmf (cayman) Ltd.	2301 Trustee
Xing Lily
Century Sunshine Limited
Decade Sunshine Limited
Lambda International Limited